e-learning
resources
ERJ
2014
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Upfront triple combination therapy in pulmonary arterial hypertension: a pilot study
Sitbon Olivier, Jaïs Xavier, Savale Laurent, Cottin Vincent, Bergot Emmanuel, Macari Elise Artaud, Bouvaist Hélène, Dauphin Claire, Picard François, Bulifon Sophie, Montani David, Humbert Marc, Simonneau Gérald
Source:
Eur Respir J 2014; 43: 1691-1697
Journal Issue:
June
Disease area:
Pulmonary vascular diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
Sitbon Olivier, Jaïs Xavier, Savale Laurent, Cottin Vincent, Bergot Emmanuel, Macari Elise Artaud, Bouvaist Hélène, Dauphin Claire, Picard François, Bulifon Sophie, Montani David, Humbert Marc, Simonneau Gérald. Upfront triple combination therapy in pulmonary arterial hypertension: a pilot study. Eur Respir J 2014; 43: 1691-1697
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
The definition of pulmonary hypertension: history, practical implications and current controversies
Should we screen for hereditary pulmonary hypertension?
Patient with ankylosing spondylitis and pulmonary hypertension
Related content which might interest you:
Upfront triple combination therapy in severe paediatric pulmonary arterial hypertension
Source: Eur Respir J, 57 (1) 2001120; 10.1183/13993003.01120-2020
Year: 2021
Upfront combination therapy in the treatment of scleroderma-associated pulmonary arterial hypertension: Results of an open label trial
Source: International Congress 2015 – Pulmonary hypertension: new treatment insights
Year: 2015
Beyond a single pathway: combination therapy in pulmonary arterial hypertension
Source: Eur Respir Rev 2016; 25: 408-417
Year: 2016
Initial dual oral combination therapy in pulmonary arterial hypertension
Source: Eur Respir J 2016; 47:1727-1736
Year: 2016
Response to exercise in patients with pulmonary arterial hypertension treated with combination therapy
Source: ERJ Open Res, 7 (1) 00725-2020; 10.1183/23120541.00725-2020
Year: 2021
Dipyridamole as adjuvant therapy in patients with pulmonary arterial hypertension. A pilot study
Source: Annual Congress 2007 - Pulmonary hypertension: diagnosis and treatment
Year: 2007
Optimal management of severe pulmonary arterial hypertension
Source: Eur Respir Rev 2011; 20: 254-261
Year: 2011
Time to combination therapy for sildenfail monotherapy in pulmonary artery hypertension (PAH). A comparison with the reported experience with bosentan
Source: Annual Congress 2013 –Pulmonary circulation: clinical treatment
Year: 2013
Upfront triple therapy for pulmonary arterial hypertension: is three a crowd or critical mass?
Source: Eur Respir J 2014; 43: 1556-1559
Year: 2014
Metformin added to bosentan therapy in patients with pulmonary arterial hypertension associated with congenital heart defects: a pilot study
Source: ERJ Open Res, 4 (3) 00060-2018; 10.1183/23120541.00060-2018
Year: 2018
Challenges in the diagnosis and treatment of pulmonary arterial hypertension
Source: Eur Respir Rev 2012 21: 313-320
Year: 2012
Clinical trial design and new therapies for pulmonary arterial hypertension
Source: Eur Respir J, 53 (1) 1801908; 10.1183/13993003.01908-2018
Year: 2019
The role of combination therapy in managing pulmonary arterial hypertension
Source: Eur Respir Rev 2014; 23: 469-475
Year: 2014
Initial combination therapy with epoprostenol and bosentan in severe pulmonary arterial hypertension
Source: Annual Congress 2009 - Pulmonary arterial hypertension
Year: 2009
Initial combination therapy with ambrisentan (AMB) and tadalafil (TAD) in treatment naïve patients with pulmonary arterial hypertension (PAH): Efficacy and safety in the AMBITION study intent to treat (ITT) population
Source: International Congress 2015 – Pulmonary hypertension: new treatment insights
Year: 2015
Riociguat for the treatment of pulmonary arterial hypertension: a long-term extension study (PATENT-2)
Source: Eur Respir J 2015; 45: 1303-1313
Year: 2015
Combination therapy with sildenafil and sitaxentan therapy for pulmonary arterial hypertension
Source: Annual Congress 2008 - Pulmonary vascular disease and other pulmonary conditions: miscellaneous
Year: 2008
Dipyridamol as adjuvant therapy in patients with pulmonary arterial hypertension (PAH)
Source: Eur Respir J 2005; 26: Suppl. 49, 562s
Year: 2005
Pulmonary arterial hypertension: combination therapy in the modern management era
Source: Eur Respir Rev 2010 19: 348-349
Year: 2010
REPLACE: A prospective, randomized trial of riociguat replacing phosphodiesterase 5 inhibitor therapy in patients with pulmonary arterial hypertension who are not at treatment goal
Source: International Congress 2017 – PAH and CTEPH
Year: 2017
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept